Last edition
News about "Symbicort Turbuhaler Inhalation Powder "
AstraZeneca India Gets NPPA Show-Cause Notice Over Alleged Overcharging of Symbicort Turbuhaler
AstraZeneca Pharma India has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA) for allegedly overcharging on its Symbicort Turbuhaler Inhalation Powder (60 doses).
Symbicort Turbuhaler Inhalation Powder | 12/09/2025 | By Dineshwori | 114
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members